PFS events confirmed by BICR in the Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results